Pharvaris announced abstract acceptances for the 2025 National Summit on hereditary angioedema, featuring multiple poster presentations on deucrictibant.

The U.S. Food and Drug Administration has approved Andembry (garadacimab-gxii) as the only treatment targeting factor XIIa for prophylactic use to prevent attacks of hereditary angioedema (HAE).

The antibody-based drug Andembry is the first to target factor XIIa, a protein responsible for swelling in people with this rare genetic disorder.

Andembry is the first prophylactic therapy for hereditary angioedema to target factor XIIa, inhibiting the top of the inflammatory cascade that drives attacks.

The changing therapeutic landscape for urticaria, angioedema, and anaphylaxis is evidenced by emerging treatments reported at AAAAI and discussed by Dr Ruchi Gupta.

Hereditary angioedema (HAE) is a rare condition that causes fluid to build up throughout your body, triggering sudden and repeated serious swelling. This is the most common type and happens ...

Because HAE, a rare genetic disorder, is so rare and because swelling can be a nonspecific symptom, many cases are initially missed or misdiagnosed, leading to delays in diagnosis.

Angioedema is a well-known side effect of treatment with an angiotensin-converting enzyme (ACE) inhibitor and one that we have been willing to accept in view of the incidence of the problem and ...

ANSWER: Valsartan, which is in the class of blood pressure medicines called the angiotensin receptor blockers, typically does increase blood potassium levels, so 5.5 mmol/L is not an uncommon ...

Dear E.S.: Valsartan, which is in the class of blood pressure medicines called the angiotensin receptor blockers, typically does increase blood potassium levels, so 5.5 mmol/L is not an uncommon ...

The FDA has accepted the NDA for donidalorsen for the prophylactic treatment of hereditary angioedema in patients aged 12 years and older.